ACTRN12622001040752尚未招募未知
A Pilot, Safety, Feasibility and Efficacy Trial of Hemoperfusion during Continuous Renal Replacement Therapy in Critically Ill Patients with Combined Liver and Kidney Failure
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Liver failure and severe acute kidney injury requiring continuous renal replacement therapy
- •Expected to continue to receive continuous renal replacement therapy for equal to or greater than 48 hours from the time of enrolment
排除标准
- •Suspected or confirmed pregnancy
- •Do not resuscitate (DNR) order in place
- •Do not intubate (DNI) order in place
- •Death is deemed inevitable or imminent during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment
- •Known human immunodeficiency virus (HIV) infection
- •Another illness is present that in the investigator’s judgement, will substantially increase the risk associated with the participants participant in the study
研究者
相似试验
已完成
1 期
A Safety and Efficacy Trial to Assess Green-Lipped Mussel extract in the treatment of Osteoarthritis of the KneeACTRN12611000517976Good Health Australia Pty Ltd20
已完成
不适用
Pilot trial on safety, feasibility and effectiveness of Osteopathic MANipulative Treatment following major abdominal surgeryDRKS00007800niversitätsklinikum Heidelberg20
进行中（未招募）
不适用
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM(Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY- EXTended treatment. The AMPLIFY-EXT study)+ Protocol Amendment 01 (version 1.0 dated 21-Apr-08) Site-specific - Molecular Profiling Supplement Samples For Pfizer’s Exploratory Research BiobankRevised Protocol 03 (version 5.0 dated 18-Apr-2011) incorporating Amendment 05 (version 210 dated 18-Apr-2011)EUCTR2007-004953-27-CZBristol-Myers Squibb International Corporation2,430
进行中（未招募）
1 期
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISMENSAYO PARA EVALUAR LA EFICACIA Y SEGURODAD DEL USO DE APIXABAN EN EL TRATAMIENTO AMPLIADO DE LA TROMBOSIS VENOSA PROFUNDA Y LA EMBOLIA PULMONAR Revised Protocol 01 (version 4.0 dated 21-Apr-08), incorporating Amendment 02 (version 1.0 dated 21-Apr-08)+ Protocol Amendment 01 (version 1.0 dated 21-Apr-08) Site-specific - Molecular Profiling Supplement Samples For Pfizer’s Exploratory Research BiobankProtocolo revisado 01 (versión 4.0 de fecha 21-Abril-08). Incorpora la enmienda 02 (versión 1.0 de fecha 21-Abril-08) + Enmienda del protocolo 01 (versión 1.0 de fecha 21-Abril-08)Venous Thromboembolism (VTE)Tromboembolismo venoso (TEV)MedDRA version: 9.1Level: PTClassification code 10051055Term: Deep vein thrombosisMedDRA version: 9.1Level: PTClassification code 10037377Term: Pulmonary embolismEUCTR2007-004953-27-ESBristol-Myers Squibb International Corporation2,430
进行中（未招募）
1 期
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary EmbolismEUCTR2007-004953-27-GBBristol-Myers Squibb International Corporation2,430